Cohort study enrolled high-risk Hodgkin Lymphoma patients in first relapse after induction therapy followed after remission either with a systemic imaging-based surveillance (Imaging cohort) or with standard clinical-based surveillance (standard cohort).
Study Type
OBSERVATIONAL
Enrollment
123
Event Free Survival (EFS)
Events: * refractoriness * relapse * death
Time frame: Time period from the first relapse after induction therapy to the date of an event (refractoriness, relapse, or death) or the last follow-up visit after autologous stem cell transplantation (ASCT), up to 2 years
EFS for clinically silent relapses
Events: * refractoriness * relapse * death
Time frame: Time period from the first relapse after induction therapy to the date of an event (refractoriness, relapse, or death) or the last follow-up visit after autologous stem cell transplantation (ASCT), up to 2 years
Response rate
Rate of response
Time frame: After salvage therapy and autologous stem cell transplantation (ASCT), up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.